Clinical Updates
Latest news
1025 articles · 20 / page
Expanding the Role of Stereotactic Radiosurgery in Small Cell Lung Cancer with Brain Metastases: Insights from a Prospective Multicenter Phase II Trial
A prospective phase II trial shows stereotactic radiosurgery offers a low neurologic death rate in SCLC patients with 1-10 brain metastases, challenging the traditional favoring of whole-brain radiation therapy.
Innovative Combination of Cryoablation and Intratumoral Immunotherapy Extends Survival in Advanced Metastatic Cancer
A phase II trial demonstrates that multiplex intratumoral immunotherapy combining cryoablation with low-dose immune checkpoint inhibitors significantly prolongs median overall survival to 20.9 months in treatment-refractory metastatic solid
PegIFN Alpha-2a Therapy Reduces Relapse Risk after NUC Discontinuation in HBeAg-Negative Chronic Hepatitis B: Insights from a Randomized Controlled Trial
Switching from nucleo(s)tide analogues to pegylated interferon alpha-2a significantly lowers virological relapse and boosts HBsAg clearance in HBeAg-negative chronic hepatitis B patients after treatment cessation.
Rapirosiran: A Promising RNA Interference Therapy Targeting HSD17B13 for Metabolic Dysfunction-Associated Steatohepatitis
This phase I randomized study shows rapirosiran, an RNAi therapeutic targeting HSD17B13, is safe and effectively reduces liver HSD17B13 mRNA in patients with metabolic dysfunction-associated steatohepatitis (MASH).
Sequential Pegylated Interferon after Bepirovirsen Lowers Relapse Risk in Chronic Hepatitis B: Insights from the B-Together Trial
The B-Together phase IIb study demonstrates that sequential therapy with bepirovirsen followed by pegylated interferon-α-2a reduces post-treatment relapse in chronic hepatitis B patients on stable nucleos(t)ide analogue therapy, with enhanc
Predictive Power of Circulating Tumor DNA in Managing Resected Extrahepatic Cholangiocarcinoma
Monitoring circulating tumor DNA (ctDNA) post-surgery accurately predicts recurrence risk in extrahepatic cholangiocarcinoma, guiding personalized adjuvant chemotherapy decisions and improving patient outcomes.
Enhancing Fibrosis Scoring in MASH: The Role of AI-Enhanced Digital Pathology
AI-assisted digital pathology improves inter-pathologist agreement on fibrosis staging in metabolic dysfunction-associated steatohepatitis (MASH), enhancing clinical trial accuracy and efficiency.
HEC88473 Dual GLP-1/FGF21 Agonist: Advancing Treatment for MASLD and T2DM with Promising Safety and Efficacy
A phase Ib/IIa trial demonstrated that HEC88473, a novel GLP-1/FGF21 dual agonist, is generally safe, effectively reduces liver fat, and improves glycemic and lipid profiles in MASLD patients with type 2 diabetes within five weeks of treatm
AZD2693: Targeting PNPLA3 148M Variant as a Precision Therapy for Metabolic Steatohepatitis
AZD2693, a liver-directed antisense oligonucleotide, safely reduces PNPLA3 expression and liver fat in homozygous PNPLA3 148M carriers with metabolic dysfunction-associated steatohepatitis, signaling promise for precision treatment in this
Rapirosiran: A Promising RNAi Therapy Targeting HSD17B13 in Metabolic Dysfunction-Associated Steatohepatitis
This phase I study evaluates rapirosiran, an RNA interference therapeutic targeting HSD17B13, demonstrating safety, tolerability, and significant liver mRNA reduction in patients with metabolic dysfunction-associated steatohepatitis (MASH).
The THEMATIC Trial: Advancing Microbiota Transplantation to Prevent Hepatic Encephalopathy Recurrence in Cirrhosis
The THEMATIC phase II trial demonstrates that fecal microbiota transplantation (FMT) is safe and reduces HE recurrence in cirrhosis, independent of dose, route, or donor diet, with gut microbiota engraftment linked to clinical outcomes.
Pan-PPAR Agonist Lanifibranor: A Breakthrough in Improving Insulin Resistance and Hepatic Steatosis in T2D and MASLD Patients
Lanifibranor, a pan-PPAR agonist, significantly reduces liver fat and improves insulin sensitivity at multiple tissue sites in type 2 diabetes patients with MASLD, offering a new therapeutic avenue to address underlying metabolic dysfunctio
Icosabutate in Metabolic Dysfunction-Associated Steatohepatitis: Insights from the Phase IIb ICONA Trial
A phase IIb trial of the FFAR1/FFAR4 agonist icosabutate in MASH shows encouraging fibrosis improvement and biomarker responses despite not meeting the primary endpoint, supporting further development.
Icosabutate and FFAR1/FFAR4 Agonism in Metabolic Dysfunction-Associated Steatohepatitis (MASH): Insights from the ICONA Phase IIb Trial
The phase IIb ICONA trial evaluated icosabutate, a dual FFAR1/FFAR4 agonist, in patients with MASH, showing fibrosis improvement without meeting the primary endpoint, and supporting further development particularly in advanced fibrosis and
Phase III NuTide:121 Trial Shows NUC-1031/Cisplatin Fails to Improve Survival Over Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer
The NuTide:121 phase III trial compared NUC-1031/cisplatin to gemcitabine/cisplatin in treatment-naïve advanced biliary tract cancer but was terminated early due to lack of survival benefit and increased liver toxicity with NUC-1031.
Maintaining Quality of Life While Extending Survival: HRQoL Outcomes from KEYNOTE-966 in Advanced Biliary Tract Cancer
The KEYNOTE-966 trial demonstrates that adding pembrolizumab to gemcitabine and cisplatin improves overall survival in advanced biliary tract cancer patients without compromising health-related quality of life.
Five-Year Survival Outcomes Confirm STRIDE’s Breakthrough in Unresectable Hepatocellular Carcinoma
The HIMALAYA trial demonstrates durable overall survival benefits and manageable safety of STRIDE (tremelimumab plus durvalumab) versus sorafenib in unresectable hepatocellular carcinoma after five years of follow-up.
Comparing the PREVENT and PCE Models for 10-Year ASCVD Risk Prediction: Insights from a Large Real-World Cohort
This review evaluates PREVENT versus PCE models for estimating 10-year ASCVD risk focusing on accuracy in patients with and without statin therapy, highlighting implications for personalized prevention.
Vericiguat in Stable HFrEF Patients: No Improvement in Composite Endpoint but Significant Reduction in Cardiovascular and All-Cause Mortality – Insights from the VICTOR Trial
The VICTOR trial in stable HFrEF patients shows vericiguat does not significantly reduce the composite of cardiovascular death or heart failure hospitalization but lowers cardiovascular and all-cause mortality, highlighting its potential fo
Browse by specialty
Open language-specific specialty feeds and department pages.